Doctor profile · Federal record
Dr. Richa Shukla
Gastroenterology Physician (CMS: Gastroenterology) · Houston, TX
- NPI 1992029979
- Accepts Medicare
- MIPS 77.8 / 100 · 2023
- 16 yrs in practice
- Female
- Group practice
- No sanctions
Practice & contact
Operates at 2 locations .
- Primary practice
-
1504 Taub Loop
Houston, TX 770301608
(713) 873-8890 - Additional location
-
7200 Cambridge St, Suite 10C
Houston, TX 770304202
(713) 798-0946 - Mailing address
-
7200 Cambridge St, Suite 10C
Houston, TX 770304202
Credentials & registration
- NPI registered
- March 2010 — 16 yrs on file
- Profile last updated
- December 23, 2025
- Year of graduation
- 2010 — 16 yrs since
- Specialty taxonomy
- 207RG0100X — NUCC code
- State license (1)
- Texas #P6083
Federal sanctions & exclusions
No sanctions, exclusions or revocations on file
Checked against OIG LEIE on NPI 1992029979. Last verified May 11, 2026.Medicare procedures · 2023
Top services delivered
Total services
22,041
Distinct HCPCS
10
Medicare allowed
$822,714
| HCPCS | Description | Services | Patients | Avg allowed | |
|---|---|---|---|---|---|
J2350 |
Injection, ocrelizumab, 1 mg | 8,700 | 12 | $57 | |
J1602 |
Injection, golimumab, 1 mg, for intravenous use | 4,750 | 11 | $13 | |
J0897 |
Injection, denosumab, 1 mg | 3,780 | 48 | $23 | |
J1745 |
Injection, infliximab, excludes biosimilar, 10 mg | 3,610 | 17 | $33 | |
J7050 |
Infusion, normal saline solution, 250 cc | 260 | 94 | $1 | |
96413 |
Administration of chemotherapy into vein, 1 hour or less | 185 | 75 | $131 | |
96415 |
Administration of chemotherapy into vein, each additional hour | 121 | 39 | $28 | |
96365 |
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 114 | 45 | $65 | |
96401 |
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 103 | 61 | $75 | |
J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg | 97 | 27 | $5 |
In context: peer comparison
Among 86 peers in this city , average services per provider: 77. This provider delivers 286× the peer median.Open Payments
Industry payments received
All-time total
$30,657
Transactions
92
Manufacturers
10
| Payer (manufacturer) | Industry | Txns | Amount |
|---|---|---|---|
| ABBVIE INC. | 64 | $28,336.23 | |
| Janssen Scientific Affairs, LLC | 2 | $1,741.49 | |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $242.48 | |
| Janssen Biotech, Inc. | 5 | $164.77 | |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $59.95 | |
| Phathom Pharmaceuticals, Inc. | 2 | $40.31 | |
| Merck Sharp & Dohme LLC | 1 | $21.18 | |
| ORPHALAN INC | 1 | $18.14 | |
| Madrigal Pharmaceuticals | 1 | $17.73 | |
| Intercept Pharmaceuticals, Inc. | 1 | $14.55 |
By nature of payment
Medicare Part D · 2023
Top prescriptions
Total claims
253
Patients
31
Total drug cost
$1,524,029
| Drug | Type | Claims | Patients | Total cost |
|---|---|---|---|---|
| Stelara (Ustekinumab) | Brand | 40 | 0 | $1,074,327 |
| Omeprazole | Generic | 27 | 12 | $637 |
| Sulfasalazine | Generic | 24 | 0 | $1,248 |
| Humira Pen (Adalimumab) | Brand | 22 | 0 | $138,556 |
| Amitriptyline Hcl | Generic | 20 | 0 | $396 |
| Sod Sulf-Potass Sulf-Mag Sulf (Sodium, Potassium,mag Sulfates) | Brand | 20 | 19 | $1,604 |
| Azathioprine | Generic | 18 | 0 | $1,928 |
| Mesalamine | Generic | 17 | 0 | $14,917 |
| Mesalamine Er (Mesalamine) | Brand | 17 | 0 | $9,084 |
| Budesonide Ec (Budesonide) | Brand | 15 | 0 | $4,232 |
Hospital affiliations
Frequently asked questions
What is Dr. Richa Shukla's medical specialty?
Dr. Richa Shukla practices Gastroenterology Physician in Houston, TX.
Where does Dr. Richa Shukla practice?
Dr. Richa Shukla practices at 1504 Taub Loop, Houston, TX 770301608. Office phone: 7138738890.
What is Dr. Richa Shukla's NPI?
Dr. Richa Shukla's National Provider Identifier (NPI) is 1992029979, issued by NPPES.
Does Dr. Richa Shukla accept Medicare assignment?
Yes. Dr. Richa Shukla accepts Medicare assignment, meaning Medicare-allowed amounts are accepted as full payment for covered services.
What procedures does Dr. Richa Shukla commonly perform?
Top Medicare-reported procedures in 2023: Injection, ocrelizumab, 1 mg (HCPCS J2350); Injection, golimumab, 1 mg, for intravenous use (HCPCS J1602); Injection, denosumab, 1 mg (HCPCS J0897). Source: CMS Medicare Physician & Other Practitioners file.